Madrigal Pharmaceuticals Stock Analysis

MDGL Stock  USD 329.24  12.15  3.83%   
Madrigal Pharmaceuticals is overvalued with Real Value of 307.28 and Target Price of 318.25. The main objective of Madrigal Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Madrigal Pharmaceuticals is worth, separate from its market price. There are two main types of Madrigal Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Madrigal Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Madrigal Stock Analysis Notes

About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 25.02. Madrigal Pharmaceuticals last dividend was issued on the 25th of July 2016. The entity had 1:35 split on the 25th of July 2016. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. Madrigal Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people. To find out more about Madrigal Pharmaceuticals contact William Sibold at 267 824 2827 or learn more at https://www.madrigalpharma.com.

Madrigal Pharmaceuticals Investment Alerts

Madrigal Pharmaceuticals had very high historical volatility over the last 90 days
Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 85.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Madrigal shares rise as Oppenheimer lifts target to 400

Madrigal Pharmaceuticals Upcoming and Recent Events

22nd of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Madrigal Largest EPS Surprises

Earnings surprises can significantly impact Madrigal Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-08-10
2017-06-30-0.6-0.69-0.0915 
2017-11-09
2017-09-30-0.79-0.680.1113 
2018-08-07
2018-06-30-0.63-0.450.1828 
View All Earnings Estimates

Madrigal Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Madrigal Pharmaceuticals' ESG score is a quantitative measure that evaluates Madrigal Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Madrigal Pharmaceuticals' operations that may have significant financial implications and affect Madrigal Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Madrigal Pharmaceuticals Thematic Classifications

In addition to having Madrigal Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Madrigal Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-06-30
399.9 K
Artisan Partners Limited Partnership2024-06-30
345.1 K
Rock Springs Capital Management Lp2024-06-30
245.5 K
Bank Of America Corp2024-06-30
239.6 K
Arrowmark Colorado Holdings, Llc (arrowmark Partners)2024-06-30
187.4 K
Braidwell Lp2024-09-30
183.8 K
Ubs Group Ag2024-06-30
173.2 K
Goldman Sachs Group Inc2024-06-30
171.5 K
Armistice Capital, Llc2024-06-30
150 K
Hhg Plc2024-06-30
2.5 M
Paulson & Company Inc2024-09-30
M
Note, although Madrigal Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Madrigal Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.92 B.

Madrigal Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.58)(0.61)
Return On Capital Employed(0.73)(0.77)
Return On Assets(0.58)(0.61)
Return On Equity(0.92)(0.88)

Management Efficiency

Madrigal Pharmaceuticals has return on total asset (ROA) of (0.5225) % which means that it has lost $0.5225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2976) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.61. The value of Return On Capital Employed is expected to slide to -0.77. At this time, Madrigal Pharmaceuticals' Total Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 3.3 M this year, although the value of Non Currrent Assets Other will most likely fall to about 719.9 K.
Last ReportedProjected for Next Year
Book Value Per Share 21.69  20.61 
Tangible Book Value Per Share 21.69  20.61 
Enterprise Value Over EBITDA(11.43)(12.00)
Price Book Value Ratio 10.67  11.20 
Enterprise Value Multiple(11.43)(12.00)
Price Fair Value 10.67  11.20 
Enterprise Value4.3 B4.6 B
At Madrigal Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin
(1.87)
Beta
(0.47)
Return On Assets
(0.52)
Return On Equity
(1.30)

Technical Drivers

As of the 22nd of November, Madrigal Pharmaceuticals secures the Downside Deviation of 2.43, mean deviation of 2.57, and Risk Adjusted Performance of 0.0748. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Madrigal Pharmaceuticals, as well as the relationship between them. Please verify Madrigal Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Madrigal Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 329.24 per share. Given that Madrigal Pharmaceuticals has jensen alpha of 0.3661, we recommend you to check Madrigal Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Madrigal Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Madrigal Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Madrigal Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Madrigal Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Madrigal Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Madrigal Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Madrigal Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Taub Rebecca few days ago
Disposition of 945 shares by Taub Rebecca of Madrigal Pharmaceuticals at 244.7881 subject to Rule 16b-3
 
Friedman Paul A over a month ago
Acquisition by Friedman Paul A of 26270 shares of Madrigal Pharmaceuticals at 9.45 subject to Rule 16b-3
 
Craves Fred B over a month ago
Disposition of 000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3
 
Taub Rebecca over two months ago
Disposition of 18917 shares by Taub Rebecca of Madrigal Pharmaceuticals at 245.3356 subject to Rule 16b-3
 
Craves Fred B over two months ago
Disposition of 15000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3
 
William Sibold over two months ago
Disposition of 6363 shares by William Sibold of Madrigal Pharmaceuticals at 243.83 subject to Rule 16b-3
 
Shannon Kelley over three months ago
Acquisition by Shannon Kelley of 7820 shares of Madrigal Pharmaceuticals at 244.5 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Acquisition by Baker Bros. Advisors Lp of 2210 shares of Madrigal Pharmaceuticals at 280.04 subject to Rule 16b-3
 
Robert Waltermire over three months ago
Disposition of 1900 shares by Robert Waltermire of Madrigal Pharmaceuticals at 280.0 subject to Rule 16b-3
 
Craves Fred B over six months ago
Disposition of 12489 shares by Craves Fred B of Madrigal Pharmaceuticals at 105.08 subject to Rule 16b-3
 
Richard Levy over six months ago
Acquisition by Richard Levy of 6000 shares of Madrigal Pharmaceuticals at 111.06 subject to Rule 16b-3
 
Paul Friedman over six months ago
Disposition of 4866 shares by Paul Friedman of Madrigal Pharmaceuticals at 248.5907 subject to Rule 16b-3

Madrigal Pharmaceuticals Outstanding Bonds

Madrigal Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Madrigal Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Madrigal bonds can be classified according to their maturity, which is the date when Madrigal Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Madrigal Pharmaceuticals Predictive Daily Indicators

Madrigal Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Madrigal Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Madrigal Pharmaceuticals Corporate Filings

13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F4
8th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
31st of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
17th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
11th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of August 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
15th of August 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify

Madrigal Pharmaceuticals Forecast Models

Madrigal Pharmaceuticals' time-series forecasting models are one of many Madrigal Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Madrigal Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Madrigal Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Madrigal Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Madrigal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Madrigal Pharmaceuticals. By using and applying Madrigal Stock analysis, traders can create a robust methodology for identifying Madrigal entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(491.21)(466.65)
Operating Profit Margin(476.75)(452.91)
Net Loss(491.21)(466.65)

Current Madrigal Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Madrigal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Madrigal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
318.25Strong Buy17Odds
Madrigal Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Madrigal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Madrigal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Madrigal Pharmaceuticals, talking to its executives and customers, or listening to Madrigal conference calls.
Madrigal Analyst Advice Details

Madrigal Stock Analysis Indicators

Madrigal Pharmaceuticals stock analysis indicators help investors evaluate how Madrigal Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Madrigal Pharmaceuticals shares will generate the highest return on investment. By understating and applying Madrigal Pharmaceuticals stock analysis, traders can identify Madrigal Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow331.5 M
Long Term Debt115.5 M
Common Stock Shares Outstanding18.7 M
Total Stockholder Equity405.3 M
Property Plant And Equipment Net3.3 M
Cash And Short Term Investments634.1 M
Cash99.9 M
Accounts Payable28 M
Net Debt17.3 M
50 Day M A248.3872
Total Current Liabilities118.5 M
Other Operating Expenses380.5 M
Non Current Assets Total3.3 M
Stock Based Compensation49.7 M
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.02)
Revenue Per Share
3.705
Return On Assets
(0.52)
Return On Equity
(1.30)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.